In this scenario of oncogenic PI3K-AKT-mTOR signalling and NRF2 activation, tumour cells can increase antioxidant systems, GSH in particular, to mitigate oxidative stress, which in turn results in drug resistance [26,47]. Here, NFE2L2 is linked to neoplasm.